Report Overview

The Glaucoma Drug market size in Kenya stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Glaucoma is characterized by the loss of the retinal ganglion cells and their axons that make up the optic nerve, which results in a cupping of the optic nerve head. This leads to optic nerve damage and visual field loss. Raised intraocular pressure (IOP) is the primary risk factor for glaucoma. Consequently, treatment options for glaucoma are developed around lowering the IOP. Glaucoma impacts negatively on the quality of life and may influence daily activities such as driving, walking and economic activities. The effect is worse with worsening of glaucoma severity and when both eyes are affected. In Kenya it is estimated that 4.3% of persons aged above 50 years have the glaucoma disease. Hence the Glaucoma Drug market in Kenya will experience enormous growth during the forecasted period.



Market Drivers

The market is majorly driven by the rising prevalence of Glaucoma in Kenya. The risk factors for Glaucoma include African race, older age, high intraocular pressure (IOP), family history of glaucoma, type 2 diabetes mellitus, high myopia, and thin central corneal thickness.

The Ophthalmic Division in Kenya has improved the health care and enhanced public awareness on ocular conditions such as Glaucoma. This has aided in early detection and management making patients to regain their sight at an early age.

Increase in the effective delivery of eye health care services and appropriate infrastructure for screening and detection of Glaucoma will propel growth in the Glaucoma drug market during the forecast period.

The increasing incidence of Glaucoma and increasing levels of awareness-related to Ophthalmic disease and treatments available are leading to a high growth of Glaucoma drug market in Kenya.

However, limited number of trained optometrists and human resources hamper growth of Glaucoma drug market in Kenya. Adherence to topical treatment is sufficiently poor and uncertain reimbursement policy are factors that restrict market growth.